Freenome

On World Cancer Day, Freenome stands with the global health community to reflect on how we can unite to improve the lives of those impacted by cancer. We are honored to contribute to the fight against cancer through our work in early detection, striving to identify cancer in its earliest, most treatable stages.

We were thrilled to see the enthusiasm for blood-based screening at #ASCOGI 2025. Dr. Aasma Shaukat presented exciting data from our PREEMPT CRC study in the main presentation room, including a prespecified direct standardization adjustment to the U.S. population's sex and age distribution. The results demonstrated 81.1% sensitivity for CRC, 90.4% specificity for advanced cancer neoplasia (ACN), and 13.7% sensitivity for advanced precancerous lesion (APL) in a census-adjusted population. The conference featured strong interest in blood-based testing, with experts discussing its potential to improve patient adherence and expand screening options, particularly for those who were previously hesitant to undergo screening. Further discussion focused on performance metrics and the real-world implementation of these innovative solutions in clinical practice. We thank all those who engaged in these discussions. Read our latest research publications here: https://lnkd.in/gWCzYHwt Special thanks to Dr. Aasma Shaukat, Karolina Kutnik, and Zhen Meng, Ph.D., along with the PREEMPT CRC study investigators, site staff, and participants, for their contributions to advancing early cancer screening. #ColorectalCancer #EarlyDetection #BloodBasedTesting #Freenome

Freenome is attending the ASCO-GI 2025 conference in San Francisco this week. Key analyses from PREEMPT CRC will be presented, including insights into how demographics can impact performance within a population, highlighting the value of providing adjusted estimates to align with the intended use population. Please join us January 25 at 9:15am at Rapid Oral Abstract Session C in Level 2 Ballroom and livestream. #GI25

As we look back on 2024, we extend our heartfelt gratitude to the people and partnerships that have made this year so impactful—including clinical study sites, patient advocacy groups, thought leaders, technology collaborators, and so many others. Your unwavering support and scientific contributions have been instrumental in advancing our mission to detect cancer in its earliest, most treatable stages. Collectively, we are making strides toward a future where early detection and accessible screening are the norm. We thank you for your continued partnership and commitment into 2025 and beyond, and we wish you a joyful holiday season and a happy new year!

We’re proud to join Fight Colorectal Cancer in support of the CRC Care Initiative. This groundbreaking effort is setting ambitious, actionable CRC goals to improve Colorectal Cancer screening and care. By leveraging real-world data and fostering collaboration across the industry, we’re committed to advancing health equity and addressing disparities in cancer care. Learn more about this important effort and how you can join us on this mission at https://FightCRC.org/CRCCI #ColorectalCancer #CRCCareInitiative #CancerAwareness

Earlier this week, Freenome attended the 2024 American College of Gastroenterology Annual Scientific Meeting in Philadelphia. Our participation highlighted key findings on blood-based colorectal cancer screening, cost-effectiveness, and diversity initiatives within our PREEMPT CRC study. We were honored that our poster, “Test Performance and Lesion Characteristics in Large Clinical Validation Study,” was recognized with the Presidential Poster Award. This recognition is given to less than 5% of accepted abstracts for high-quality, unique research. Congratulations to the authors on this recognition! We look forward to building on these insights and advancing efforts to close gaps in colorectal cancer care. #ACG2024 #EarlyCancerDetection #ColorectalCancer #Freenome #CRC Learn more about our research: https://lnkd.in/gWCzYHwt

Freenome is attending the American College of Gastroenterology Annual Scientific Meeting in Philadelphia from October 25-30. At Booth 574, we’ll share how our blood-based screening solutions are advancing the early detection of colorectal cancer when it’s most treatable. Our team will present key research, including insights into the projected benefits and cost-effectiveness of blood-based screening and how we’ve enhanced diversity in clinical trials to ensure better outcomes for everyone. Swipe to learn more about our presentations and how we’re working to close gaps in early cancer screening.

Last week, Riley Ennis, co-founder and Chief Product Officer at Freenome, joined Fight Colorectal Cancer and leading experts in colorectal cancer (CRC) prevention and care at a working session and dinner to unveil "The Colorectal Cancer Care Report: Improving Colorectal Cancer Prevention and Care in the United States." Freenome led the analysis for Goal 1 of the report - Timely Screening for the Prevention of CRC - to help develop standardized screening metrics that can be applied nationwide to improve screening rates and catch cancer early, when it’s most treatable. By collaborating with Fight CRC and leading experts, we can advance metrics that are grounded in solid research and widely accepted across institutions. It's a collective effort to build a standardized, data-driven approach to screening that can be scaled nationally, ultimately helping to close the care gap and save lives.

Today is World Lung Cancer Day, a time to raise awareness and support those affected by lung cancer, the leading cause of cancer deaths worldwide. At Freenome, we are developing blood tests to detect lung cancer early, when it is most treatable. The PROACT LUNG Study is intended to validate the clinical performance of a blood-based test for the early detection of lung cancer. We are currently enrolling as many as 20,000 individuals who meet specific criteria. Together, we can drive significant progress in early cancer detection. #WLCD24 #EarlyDetection #Freenome

Earlier this week, our CEO, Mike Nolan, shared his perspectives on how liquid biopsy innovations are reshaping cancer care at the 2024 Analytical, Life Science & Diagnostics Association (ALDA) Spring Senior Executive Conference in London:   “Blood-based technologies have vast potential to improve how we diagnose cancer, make treatment decisions, and monitor for disease resistance. Getting these tools into the clinic requires strong collaboration between life sciences and diagnostic companies. By working together with a shared purpose, we are determined to improve patient outcomes with innovations in liquid biopsy technologies - and set new standards of cancer care.”